Transcenta Holding names Daniel Weng as CFO

Transcenta Holding has announced the appointment of Daniel Weng as the company’s Chief Financial Officer (CFO), reporting to Xueming Qian, Chief Executive Officer (CEO). As a member of the executive leadership team, Weng will be fully responsible for the company’s financial strategy, performance reporting, capital markets activities and investor relations, helping the company to take a leap forward. Prior to joining Transcenta, he served as the vice president and Head of finance at CStone Pharmaceuticals, a company listed in HKEX, and has the overall responsibilities for financial functions, where he made tremendous contributions to commercial strategy leading to successful commercial launch in China and Taiwan as well as research and development prioritization. Prior to CStone Pharmaceuticals, he served as the vice president and head of finance at Everest Medicines, a company listed on the HKEX. He led the overall IPO team and partnered with bulge-bracket investment banks for IPO preparation and achieved a successful listing. Prior to that, Daniel served as the CFO of China at Amgen.